Business Context and Reporting Period
Company: The Cooper Companies, Inc.
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Three and six months ended April 30, 2004
Business Overview: Cooper operates two primary business units: CooperVision (CVI), which markets specialty contact lenses, and CooperSurgical (CSI), which provides medical devices and surgical instruments for gynecologists and obstetricians.
Key Financial Metrics
| Metric (in thousands) | 3 Months Ended Apr 30, 2004 |
6 Months Ended Apr 30, 2004 |
|---|---|---|
| Net Sales | $120,552 | $230,286 |
| Gross Profit | $78,385 | $148,341 |
| Gross Margin | 65% | 64% |
| Operating Income | $27,823 | $52,672 |
| Net Income | $21,699 | $40,054 |
| Diluted EPS | $0.64 | $1.19 |
| Cash from Operations (6mo) | $36,859 | |
| Total Debt | $178,749 (Short-term: $23,877; Long-term: $154,872) | |
| Cash & Equivalents | $20,731 |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 25% ($24.2M) for the quarter and 21% ($39.9M) for the six-month period compared to the prior year.
- CooperVision (CVI): Sales up 22% (quarter) and 21% (six months), driven by global market share gains in specialty lenses (toric, cosmetic, multifocal). International revenue grew 33% in the quarter.
- CooperSurgical (CSI): Sales up 39% (quarter) and 22% (six months), primarily due to recent acquisitions, with organic growth of approximately 4%.
- Profitability: Operating income rose 32% for the quarter and 29% for the six-month period. Net income increased 43% for the quarter and 38% for the six-month period.
- Acquisitions: The company completed four acquisitions during the period (SURx, Milex, Argus, and Opti-Centre), totaling approximately $42.65 million in cash payments, significantly impacting CSI's revenue and goodwill.
- Effective Tax Rate: The effective tax rate for the quarter was 21%, down from 25% in the prior year, due to a shift in business mix toward lower-tax jurisdictions.
Guidance, Outlook, and Risks
- Outlook: Management expects cash from operations and current cash balances to fund operations, capital expenditures, dividends, and smaller acquisitions. Capital expenditures for fiscal 2004 are projected at approximately $45 million, including doubling U.K. manufacturing capacity.
- Liquidity: As of April 30, 2004, the company had $143.2 million available under its KeyBank line of credit.
- Risks:
- Foreign Exchange: Exposure to fluctuations in the pound sterling and euro, affecting both debt service and operating costs.
- Interest Rates: Variable interest rates on the KeyBank credit facility expose the company to rate increases.
- Regulatory: Risks related to worldwide regulatory issues, product recalls, and healthcare reform legislation.
- Integration: Delays or costs associated with integrating recent acquisitions.
- Unusual Items: The company recorded a $365,000 charge for the settlement of disputes in the quarter. Additionally, pro forma net income (including stock-based compensation expense) would have been lower than reported figures.
Investor Verification Checklist
- Acquisition Integration: Verify the revenue contribution and margin impact of the four acquisitions (SURx, Milex, Argus, Opti-Centre) to ensure organic growth assumptions are accurate.
- Inventory Levels: Inventory increased by $13.5 million to $103.3 million; confirm that this aligns with sales growth and does not indicate obsolescence risks.
- Cash Flow Sustainability: Operating cash flow was strong ($36.9M for six months), but cash and equivalents decreased by $26.7M due to acquisition spending. Verify the sufficiency of the $143.2M credit line for future M&A and capex.
- Geographic Mix: Confirm the sustainability of the shift to lower-tax jurisdictions which improved the effective tax rate to 21%.
- Stock-Based Compensation: Review the pro forma EPS figures ($0.60 diluted for the quarter) to understand the potential impact if the company adopts fair value accounting for stock options.